Login / Signup

Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.

Josef S SmolenPhilip MeaseHasan TahirHendrik Schulze-KoopsInmaculada de la TorreLingnan LiMaja HojnikChristophe SapinMasato OkadaRoberto CaporaliJordi GratacósPhilippe GoupilleSoyi Liu LeageSreekumar PillaiPeter Nash
Published in: Annals of the rheumatic diseases (2020)
NCT03151551.
Keyphrases